1440_405-1116_628-768_432

Cardiology & Electrophysiology Symposium

Concepts & Controversies

Thank you for your interest in Dignity Health Heart and Vascular Institute of Greater Sacramento's 29th Annual Cardiology & Electrophysiology CME Symposium 2021. 

Event Details 

Saturday, October 16, 2021
7:30 a.m. to 12:10 p.m.
via Zoom

REGISTRATION IS NOW OPEN!

7:30 a.m. Exhibitors     
8:00 a.m. Welcome 
12:10 p.m. Closing Remarks/Adjourn

Our featured presentations will include:

TAVR for Everyone? Not Necessarily
Peter Block, MD, FACC, MSCAI

Mitral Regurgitation: Are Mitral Valve Transcatheter Edge to Edge Repair (TEER) Techniques the Answer?
Peter Block, MD, FACC, MSCAI

Should Ablation be First Line Therapy for Atrial Fibrillation?
Edward Gerstenfeld, MD

Arrhythmias in Mitral Valve Prolapse - When to Worry
Edward Gerstenfeld, MD

What medications and devices are beneficial for patients with HfrEf?
Wayne Levy, MD, FACC

What medications and devices are beneficial for patients with HFpEF?
Wayne Levy, MD, FACC

What is New in Coronary Interventions: 2021
Richard Heuser, MD, FACC, FACP, FESC, MSCAI

New Treatments in Peripheral Vascular Disease 
Richard Heuser, MD, FACC, FACP, FESC, MSCAI

Objectives:

At the conclusion of our program, participants should be able to implement the following changes to their professional practice:

  • Identify patients who would benefit from Transcather Aortic Valve Replacement (TAVR) versus surgery
  • Recognize the limits and outcomes of transcatheter mitral therapy use
  • Decide when it is appropriate to recommend catheter ablation as first-line therapy for atrial fibrillation
  • Risk stratify patients with Mitral Valve Prolapse (MVP) and ventricular ectopy
  • Understand which medications and devices have a meaningful reduction in mortality in patients with heart failure with a reduced ejection fraction (HFrEF)
  • Understand the importance of volume management in keeping heart failure with preserved ejection fraction (HFpEF) patients out of the hospital
  • Have a thoughtful approach to treating Coronary Microvascular Disease (MVD), chronic total occlusion (CTO), and left main/stent
  • Recognize the importance and treatment strategy in Critical Limb Ischemia (CLI)

Chairpersons:

Scott B. Baron, MD, FACC, FSCAI
Symposium Chairman
Director, Cardiac Emergency Services
Dignity Health Mercy San Juan Medical Center

Clinical Professor of Medicine
California Northstate University School of Medicine

P. Gearoid O’Neill, MD, FACC, FHRS
Symposium Co-Chairman
Director, Cardiac Electrophysiology
Dignity Health Mercy General Hospital

Joyce Higley, RD, MHA
Senior Director
Dignity Health Heart and Vascular Institute of Greater Sacramento

Anu LoCricchio, RN, MBA
Director, Cardiovascular Services
Dignity Health Heart and Vascular Institute of Greater Sacramento

Faculty:

Peter Block, MD, FACC, MSCAI
Professor Emeritus
Emory University School of Medicine
Atlanta, Georgia

Edward Gerstenfeld, MD
Professor of Medicine
Chair of Cardiac Electrophysiology
University of California, San Francisco School of Medicine
San Francisco, California

Wayne Levy, MD, FACC
Professor of Medicine
Cardiology University of Washington Heart Institute 
Seattle Washington

Richard Heuser, MD, FACC, FACP, FESC, MSCAI
Vascular Heart and Lung Associates 
Mesa, Arizona

 

Accreditation Statement:

Dignity Health Sacramento is accredited by the California Medical Association (CMA) to provide continuing medical education for physicians.

Credit Designation:

Dignity Health Sacramento designates this live activity for a maximum of 7 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.